Genentech Setback In hGH Suit
Genentech's patent infringement litigation with Biotechnology General and Novo Nordisk over their human growth hormone products has been dismissed with prejudice by US International Trade Commission Administrative Law Judge Paul Luckern. The judge found no violation in the importation or sale of BTG or Novo's hGH products, and the Commission has until March 31, 1995 to accept, reject or revise the judge's decision.
Genentech's complaint was originally filed in March 1993, and alleges that the BTG and Novo products infringe four of its US production patents. Meantime, Genentech has filed New Drug Applications for new liquid formulations of its growth hormone products Protropin (somatrem) and Nutropin (somatropin).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze